SCHEMBL6347392

SCHEMBL6347392

O=C(O)Cc1ccc(Sc2ccc(OCc3ccccc3)cc2)nc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 5/20 0.50
FFAR4 Q5NUL3 2/20 0.50
ALOX5 P09917 4/20 0.47
NR4A1 P22736 1/20 0.47
NR4A2 P43354 1/20 0.47
NR4A3 Q92570 1/20 0.47
P4HTM Q9NXG6 1/20 0.46
PPARD Q03181 1/20 0.46
NR1H4 Q96RI1 1/20 0.46
PTGDR2 Q9Y5Y4 1/20 0.46
MAOB P27338 1/20 0.45
PARP10 Q53GL7 1/20 0.45
PTGS1 P23219 2/20 0.44
PTGS2 P35354 2/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
SLC6A2 P23975 1/20 0.44
CYP2C19 P33261 1/20 0.44
SLC6A3 Q01959 1/20 0.44
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6341711 0.84 NR4A2 (0.62) NR4A1NR4A2NR4A3P4HTMNR1H4
SCHEMBL6347677 0.83 ALDH1A1 (0.46) LMNA
SCHEMBL6347648 0.81 MAOB (0.64) NR4A1NR4A2NR4A3MAOBPARP10
SCHEMBL6348830 0.80 ALDH1A1 (0.50) LMNA
SCHEMBL6339246 0.80 MAOB (0.51) NR4A1NR4A2NR4A3MAOBPARP10
SCHEMBL1066614 0.79 FFAR1 (0.70) FFAR1FFAR4ALOX5NR4A1NR4A2
SCHEMBL6338656 0.78 ACACB (0.55) FFAR1FFAR4ALOX5NR4A1NR4A2
SCHEMBL4222632 0.78 FFAR1 (0.68) FFAR1FFAR4ALOX5NR4A1NR4A2
Hydrochloric Acid SCHEMBL10622121 0.78 FFAR1 (0.68) FFAR1FFAR4ALOX5NR4A1NR4A2
Ammonia Solution, Strong SCHEMBL27788257 0.78 FFAR1 (0.68) FFAR1FFAR4ALOX5NR4A1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890932-B2 Immunoglobulin e antibody suppressors TEIJIN LIMITED (JP) 2005-05-10 US disclosed
EP-1101755-B1 ANTHRANILIC ACID DERIVATIVES TEIJIN LTD (JP) 2004-10-06 EP disclosed
US-20030232811-A1 Immunoglobulin e antibody suppressors TEIJIN LIMITED 2003-12-18 US disclosed
US-6649656-B1 Anticarcinogenic, antiallergen, antishock, and antiasthmatic agents TEIJIN LIMITED (JP) 2003-11-18 US disclosed
EP-1101755-A1 ANTHRANILIC ACID DERIVATIVES TEIJIN LIMITED (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232811-A1 Immunoglobulin e antibody suppressors IGLV6-57, FCGRT, IGSF11 FFAR1 1564/4885FFAR4 2194/4885ALOX5 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.